<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002524</url>
  </required_header>
  <id_info>
    <org_study_id>DM93-058</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-93058</secondary_id>
    <secondary_id>NCI-T93-0088D</secondary_id>
    <secondary_id>CDR0000078316</secondary_id>
    <nct_id>NCT00002524</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma</brief_title>
  <official_title>Pilot Study in AIDS-Related Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      patients with AIDS-related lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Develop an effective chemotherapy regimen with mild immunosuppressive and
      myelosuppressive properties to treat patients with AIDS-related lymphoma (ARL) who have
      severe T4 lymphopenia. II. Estimate the CR rate, lymphoma-free survival, and overall survival
      of non-T4 lymphopenic patients and patients who present with nonbulky Ann Arbor stage I ARL
      treated with standard regimens of known effectiveness. III. Evaluate the effects on long-term
      outlook of concurrent antiretroviral therapy, prophylactic antibiosis with
      trimethoprim/sulfamethoxazole or aerosolized pentamidine, and prn use of granulocyte
      colony-stimulating factor for severe myelosuppression.

      OUTLINE: Patients are assigned to Regimens A, B, and C according to histology and extent of
      disease and the degree of immunosuppression as follows: Regimen A: Patients with Ann Arbor
      stage I intermediate grade or immunoblastic lymphoma with measurable nonbulky disease (less
      than 7 cm), low LDH (less than 686), and no prior opportunistic infection irrespective of T4
      count; also those with nonmeasurable stage I extranodal primaries (infiltration of less than
      2/3 of an organ site, e.g., stomach, rectum, esophagus, sinus cavity) irrespective of T4
      count. Regimen B: All patients (except primary brain lymphoma patients) not assigned to
      Regimen A who have T4 counts of at least 200 and no history of opportunistic infection;
      includes all stages of small noncleaved cell lymphoma and bulky stage I and stages II-IV
      intermediate grade and immunoblastic lymphoma. Regimen C: Patients not assigned to Regimen A
      or B, i.e., those with T4 counts less than 200 and/or a history of opportunistic infection
      and those with primary brain lymphoma. The following acronyms are used: ARA-C Cytarabine,
      NSC-63878 BLEO Bleomycin, NSC-125066 CDDP Cisplatin, NSC-119875 CF Leucovorin calcium,
      NSC-3590 CTX Cyclophosphamide, NSC-26271 DOX Doxorubicin, NSC-123127 5-FU Fluorouracil,
      NSC-19893 G-CSF Granulocyte Colony-Stimulating Factor (Amgen), NSC-614629 IFF Ifosfamide,
      NSC-109723 MePRDL Methylprednisolone succinate Mesna Mercaptoethane sulfonate, NSC-113891 MTX
      Methotrexate, NSC-740 PRED Prednisone, NSC-10023 VCR Vincristine, NSC-67574 VP-16 Etoposide,
      NSC-141540 ZDV Zidovudine, NSC-602670 Regimen A: 5-Drug Combination Chemotherapy followed by
      Radiotherapy. CHOP-BLEO: CTX; DOX; VCR; PRED; BLEO; followed by involved-field irradiation
      with megavoltage equipment. Regimen B: 4-Drug Combination Chemotherapy alternating with
      3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy. ASHAP: DOX; MePRDL;
      ARA-C; CDDP; alternating with IMVP-16: IFF/Mesna; MTX/CF; VP-16; followed, in selected
      patients with initially bulky localized disease, by involved-field irradiation with
      megavoltage equipment. Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation
      followed, as indicated, by Radiotherapy. FLEP: 5-FU/CF/CDDP; followed, in selected patients
      with initially bulky localized disease, by involved-field irradiation with megavoltage
      equipment. Prior to starting chemotherapy, patients with primary brain lymphoma receive a
      course of cranial irradiation using accelerator beams with photon energies of 6-15 MV.

      PROJECTED ACCRUAL: Up to 92 patients (10 for Regimen A, 28 for Regimen B, 54 for Regimen C)
      will be entered over 3 years. If there are no CRs among the first 6 patients on Regimens A
      and B or the first 19 patients on Regimen C, accrual to that regimen will cease. If more than
      4 infectious deaths occur among the first 10 patients or if the rate of disease progression
      exceeds 20% on any regimen, further accrual to that regimen will cease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1993</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Clinical Response</measure>
    <time_frame>3 Years</time_frame>
    <description>Clinical Responses categorized by: Complete Response (CR), Partial Response (PR), Minor Response, Stable Disease or Progressive Disease</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bleomycin Sulfate</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <other_name>Blenoxane</other_name>
    <other_name>BLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Plationol-AQ</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytarabine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride (DOX)</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Efudex</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Citrovorum</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Pentam-300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>SMX</other_name>
    <other_name>Bactrim</other_name>
    <other_name>Cotrim</other_name>
    <other_name>Septra</other_name>
    <other_name>Sulfamethoprim</other_name>
    <other_name>Sulfatrim</other_name>
    <other_name>Sulfoxaprim</other_name>
    <other_name>Trisulfam</other_name>
    <other_name>Uroplus</other_name>
    <other_name>Co-trimoxazole</other_name>
    <other_name>SMX-TMP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (AZT)</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Retrovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>RT</other_name>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Previously untreated, HIV-related intermediate- and high-grade
        lymphoma with no previous diagnosis of Kaposi's sarcoma Pathology reviewed at M.D. Anderson
        Cancer Center

        PATIENT CHARACTERISTICS: Age: Over 15 Performance status: Not specified Hematopoietic: Not
        specified Hepatic: Not specified Renal: For patients with T4 less than 200 and those with
        primary brain lymphoma: Creatinine no greater than 2.0 mg/dL (unless entry approved by
        principal investigator) Other: Serious intercurrent illness must be discussed with the
        principal investigator Infectious disease consultation required for complex infections
        Medications for other conditions allowed provided no adverse interaction with protocol
        therapy occurs No previously diagnosed Kaposi's sarcoma or other malignancy

        PRIOR CONCURRENT THERAPY: No prior therapy for lymphoma No concurrent chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W. McLaughlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>October 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>AIDS-related diffuse small cleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Pentamidine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

